SEMA3A and hepatocellular carcinoma: However, miR-192 serves as a poor prognosis marker in other cancer types including neuroblastoma targeting Dicer1 [8], gastric cancer targeting RAB11-FIP2 [46] and SMG-1 [47], NSCLC targeting the FGFR3/RB1 pathway [48], hepatocellular carcinoma targeting SEMA3A [49], and pancreatic cancer targeting SIP1 [50].